Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Seattle Area Hormone and Reproductive Epidemiology Breast Cancer Study
Not an EDRN Protocol

Seattle Area Hormone and Reproductive Epidemiology Breast Cancer Study

1035

No involved investigator sites defined.

The SHARE Study (Seattle Area Hormone And Reproductive Epidemiology Breast Cancer Study) is a five-year, population-based case-control study, funded by the National Institutes of Health, to investigate the relationship between hormone replacement therapy (HRT) and invasive lobular and invasive ductal breast cancer among women 55 to 74-years of age. The case group of 1043 women consists of 271 invasive lobular, 330 invasive ductal and lobular, and 442 invasive ductal, breast cancer cases. The control group consists of 469 controls drawn from the general population. The specific study hypotheses that were tested: 1. Is the use of combined estrogen-progestin hormone replacement therapy (CHRT) associated with an increase in the incidence of invasive lobular breast cancer in women aged 55-74a 2. Is the use of CHRT associated with an increase in the incidence of invasive ductal breast cancer in women aged 55-74a 3. Does the duration, patterns and/or recency of CHRT use influence the size of the associationa 4. Is the use of CHRT associated with particular tumor marker profiles or characteristics of lobular and ductal breast cancers

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.